EGFR and neoplasm: Having established that both CT26EGFR and HT29 had intact EGFR downstream signaling pathways, we expected Cetuximab monotherapy to result in anti-tumor activity, but used it as a control arm to differentiate the immune pertinent impact of BsAb treatment.